Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | PYGL | P06737 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 5/20 | 0.46 |
| ▸ | IDH1 | O75874 | 1/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22803824 | 0.91 | EPHX1 (0.51) | MAOAIDH1RAF1BRAFEPHX1 | |
| SCHEMBL22803592 | 0.85 | MAOA (0.51) | MAOAPYGLESR1IDH1HDAC1 | |
| SCHEMBL22803724 | 0.79 | ESR1 (0.63) | MAOAPYGLESR1IDH1HDAC1 | |
| SCHEMBL31668714 | 0.78 | ESR1 (0.61) | MAOAPYGLESR1IDH1HDAC1 | |
| SCHEMBL22803735 | 0.77 | EPHX1 (0.54) | MAOANOTUMEPHX1 | |
| SCHEMBL27371222 | 0.76 | ESR1 (0.59) | MAOAPYGLESR1IDH1HDAC1 | |
| SCHEMBL25120831 | 0.74 | ESR1 (0.58) | MAOAPYGLESR1IDH1HDAC1 | |
| SCHEMBL1012954 | 0.74 | RAF1 (0.53) | RAF1BRAFKDM1A | |
| SCHEMBL31668678 | 0.74 | ESR1 (0.57) | MAOAPYGLESR1IDH1HDAC1 | |
| SCHEMBL30052295 | 0.74 | MAOA (0.61) | MAOAPYGLESR1IDH1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2023-04-06 | — | — | US | disclosed |
| WO-2020257621-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020252240-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | STING1, CGAS, TBK1 | MAOA 4309/4885PYGL 1235/4885ESR1 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.